Voxilaprevir is a nonstructural protein 3 and 4a protease inhibitor used to treat Hepatitis C infections. Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
- Mechanism
- Curator reviewed · 1 reference
Voxilaprevir exerts its antiviral action by reversibley binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV). Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B. By inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function.
- Primary indication
- Vosevi (Voxilaprevir/DB08934/DB11613) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an...Curator reviewed · 8 structured indications
- Formula / weight
- C40H52F4N6O9S · 868.94 g/mol (avg)
- First approval
- Canada, 2017 · United States, 2017 · European Union, 2020
- Code names
- GS-9857
- Brand names
Resolves to
MZBLZLWXUBZHSL-FZNJKFJKSA-NSMILESCC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]1(C[C@H]1C(F)F)C(=O)NS(=O)(=O)C1(C)CC1)C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCC(F)(F)C1=C(O2)N=C2C=C(OC)C=CC2=N1)C(C)(C)CWhat you can answer from here — as of August 31, 2026
Which drugs share a target with Voxilaprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account